Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

The Original Article was published on 22 January 2021

Correction to: Leukemia https://doi.org/10.1038/s41375-021-01125-4, published online 22 January 2021

In Supplementary Table 2, the n numbers for the response-evaluable patients with higher-risk MDS were swapped for the pevonedistat + azacitidine arm and the azacitidine alone arm. Instead of n = 30 and n = 29 as originally published, these have now been corrected to n = 29 for pevonedistat + azacitidine and n = 30 for azacitidine. No changes were required to the response rate percentages as these were calculated using the correct denominators.

The updated files are attached to this correction.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Mikkael A. Sekeres.

Additional information

The original article can be found online at https://doi.org/10.1038/s41375-021-01125-4.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sekeres, M.A., Watts, J., Radinoff, A. et al. Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia 35, 3637 (2021). https://doi.org/10.1038/s41375-021-01473-1

Download citation

Search

Quick links